$IOVA

IOVANCE BIOTHERAPEUTICS, INC.

Iovance Biotherapeutics is a commercial-stage biopharmaceutical company that develops and delivers individualized tumor-infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. Its commercial products are Amtagvi, a one-time T cell therapy for adults with previously treated advanced melanoma, and Proleukin, an interleukin-2 product used in the Amtagvi treatment regimen and other approved oncology uses. Iovance also sells Proleukin for use in manufacturing cell therapies and in clinical and research settings. The company earns money from sales of these products through distributors and other third-party clients. Its pipeline includes TIL therapies for melanoma, non-small cell lung cancer and other solid tumors, as well as next-generation programs. Iovance manufactures most commercial Amtagvi and clinical lifileucel at its Iovance Cell Therapy Center in Philadelphia, Pennsylvania. It is headquartered in San Carlos, California.

2
3
0

No SEC Form 4 filings for $IOVA in the last 30 days.

See all $IOVA insider activity →
Med

Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb

Iovance Biotherapeutics (IOVA) reported updated clinical data for its lung cancer treatment, with a 25% response rate in 69 patients. The company plans to file for approval in 2027 and start a first-line lung study. Safety improvements were noted after regimen changes. IOVA also plans studies in melanoma and sarcoma. The company expects long-term gross margin improvement and has $382M in cash.

SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too

BlackRock and a Vanguard unit added SLS, IBRX, IOVA, MRK, and LLY to their Q3 buy lists. Lilly reported strong sales from diabetes, obesity, and cancer drugs. Sellas (SLS) awaits Phase 3 trial results for its AML treatment. ImmunityBio (IBRX) plans expanded FDA approval for Anktiva. Iovance (IOVA) saw 77% YoY sales growth for Amtagvi and is testing it with Merck's (MRK) Keytruda. Retail sentiment varies across stocks.

IOVA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning IOVA (IOVANCE BIOTHERAPEUTICS, INC.). Coverage has skewed bullish: 2 bullish, 3 neutral, and 0 bearish.

Recent IOVA coverage spans financial news, earnings and regulation.

What's driving IOVA

AlphAI scores every news story that mentions IOVA with an AI model for sentiment and relevance, and aggregates insider trades from IOVANCE BIOTHERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IOVA

Score

Iovance Biotherapeutics Targets 2027 Lung Cancer Filing as AMTAGVI Sales Climb

Iovance Biotherapeutics (IOVA) reported updated clinical data for its lung cancer treatment, with a 25% response rate in 69 patients. The company plans to file for approval in 2027 and start a first-line lung study. Safety improvements were noted after regimen changes. IOVA also plans studies in melanoma and sarcoma. The company expects long-term gross margin improvement and has $382M in cash.

$SLSHighAI 8/10

SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too

BlackRock and a Vanguard unit added SLS, IBRX, IOVA, MRK, and LLY to their Q3 buy lists. Lilly reported strong sales from diabetes, obesity, and cancer drugs. Sellas (SLS) awaits Phase 3 trial results for its AML treatment. ImmunityBio (IBRX) plans expanded FDA approval for Anktiva. Iovance (IOVA) saw 77% YoY sales growth for Amtagvi and is testing it with Merck's (MRK) Keytruda. Retail sentiment varies across stocks.

$IOVAHighAI 8/10

IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

Iovance Biotherapeutics (IOVA) reported Q3 2026 earnings with a loss of 5 cents per share, narrower than estimates. Revenue rose 80.1% YoY to $121.5M, driven by Amtagvi sales. R&D costs fell 34.4% YoY. IOVA reaffirmed 2026 revenue guidance of $410M-$420M. Shares fell 11% despite strong results.

Iovance Biotherapeutics (IOVA) Lifileucel Wins Fast Track After Strong Sarcoma Trial Data

Iovance Biotherapeutics (IOVA) announced that its treatment lifileucel showed strong efficacy in advanced soft tissue sarcomas, according to a pilot study. The FDA granted lifileucel fast track designation for these sarcomas. IOVA reported Q3 2026 revenue of $121.47M and a net loss of $22.27M. The company is expanding its TIL platform beyond melanoma into other solid tumor indications.

$IOVAHighAI 8/10

IOVANCE BIOTHERAPEUTICS, INC. (IOVA): Corporate Overview November 2026 Exhibit 99.1

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an SEC Form 8-K — Other Events. Corporate Overview November 2026 Exhibit 99.1 Exhibit 99.1 Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meani

Related tickers